GP IIb/IIIa Antagonists

Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt ves...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Kleiman, Neal S. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	1999

Schlagwörter:	Percutaneous Coronary Intervention Adis International Limited Acute Coronary Syndrome Unstable Angina Abciximab

Übergeordnetes Werk:	Enthalten in: Drugs in R & D - [S.l.] : Springer International, 1999, 1(1999), 5 vom: Mai, Seite 361-370
Übergeordnetes Werk:	volume:1 ; year:1999 ; number:5 ; month:05 ; pages:361-370

Links:	Volltext

DOI / URN:	10.2165/00126839-199901050-00001

Katalog-ID:	SPR033286841

Internformat


LEADER	01000caa a22002652 4500
001	SPR033286841
003	DE-627
005	20230519191741.0
007	cr uuu---uuuuu
008	201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00126839-199901050-00001 \|2 doi
035			\|a (DE-627)SPR033286841
035			\|a (SPR)00126839-199901050-00001-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
084			\|a 44.40 \|2 bkl
100	1		\|a Kleiman, Neal S. \|e verfasserin \|4 aut
245	1	0	\|a GP IIb/IIIa Antagonists
264		1	\|c 1999
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.
650		4	\|a Percutaneous Coronary Intervention \|7 (dpeaa)DE-He213
650		4	\|a Adis International Limited \|7 (dpeaa)DE-He213
650		4	\|a Acute Coronary Syndrome \|7 (dpeaa)DE-He213
650		4	\|a Unstable Angina \|7 (dpeaa)DE-He213
650		4	\|a Abciximab \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Drugs in R & D \|d [S.l.] : Springer International, 1999 \|g 1(1999), 5 vom: Mai, Seite 361-370 \|w (DE-627)357171527 \|w (DE-600)2094513-9 \|x 1179-6901 \|7 nnns
773	1	8	\|g volume:1 \|g year:1999 \|g number:5 \|g month:05 \|g pages:361-370
856	4	0	\|u https://dx.doi.org/10.2165/00126839-199901050-00001 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a SSG-OPC-PHA
912			\|a SSG-OPC-ASE
912			\|a GBV_ILN_20
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2190
936	b	k	\|a 44.40 \|q ASE
951			\|a AR
952			\|d 1 \|j 1999 \|e 5 \|c 05 \|h 361-370

Indexfelder

author_variant	n s k ns nsk
matchkey_str	article:11796901:1999----::piiiatg
hierarchy_sort_str	1999
bklnumber	44.40
publishDate	1999
allfields	10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370
spelling	10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370
allfields_unstemmed	10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370
allfieldsGer	10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370
allfieldsSound	10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370
language	English
source	Enthalten in Drugs in R & D 1(1999), 5 vom: Mai, Seite 361-370 volume:1 year:1999 number:5 month:05 pages:361-370
sourceStr	Enthalten in Drugs in R & D 1(1999), 5 vom: Mai, Seite 361-370 volume:1 year:1999 number:5 month:05 pages:361-370
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Percutaneous Coronary Intervention Adis International Limited Acute Coronary Syndrome Unstable Angina Abciximab
dewey-raw	610
isfreeaccess_bool	false
container_title	Drugs in R & D
authorswithroles_txt_mv	Kleiman, Neal S. @@aut@@
publishDateDaySort_date	1999-05-01T00:00:00Z
hierarchy_top_id	357171527
dewey-sort	3610
id	SPR033286841
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033286841</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519191741.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00126839-199901050-00001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033286841</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00126839-199901050-00001-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kleiman, Neal S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">GP IIb/IIIa Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Percutaneous Coronary Intervention</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Coronary Syndrome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Unstable Angina</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Abciximab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs in R & D</subfield><subfield code="d">[S.l.] : Springer International, 1999</subfield><subfield code="g">1(1999), 5 vom: Mai, Seite 361-370</subfield><subfield code="w">(DE-627)357171527</subfield><subfield code="w">(DE-600)2094513-9</subfield><subfield code="x">1179-6901</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:5</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:361-370</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00126839-199901050-00001</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1999</subfield><subfield code="e">5</subfield><subfield code="c">05</subfield><subfield code="h">361-370</subfield></datafield></record></collection>
author	Kleiman, Neal S.
spellingShingle	Kleiman, Neal S. ddc 610 bkl 44.40 misc Percutaneous Coronary Intervention misc Adis International Limited misc Acute Coronary Syndrome misc Unstable Angina misc Abciximab GP IIb/IIIa Antagonists
authorStr	Kleiman, Neal S.
ppnlink_with_tag_str_mv	@@773@@(DE-627)357171527
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1179-6901
topic_title	610 ASE 44.40 bkl GP IIb/IIIa Antagonists Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213
topic	ddc 610 bkl 44.40 misc Percutaneous Coronary Intervention misc Adis International Limited misc Acute Coronary Syndrome misc Unstable Angina misc Abciximab
topic_unstemmed	ddc 610 bkl 44.40 misc Percutaneous Coronary Intervention misc Adis International Limited misc Acute Coronary Syndrome misc Unstable Angina misc Abciximab
topic_browse	ddc 610 bkl 44.40 misc Percutaneous Coronary Intervention misc Adis International Limited misc Acute Coronary Syndrome misc Unstable Angina misc Abciximab
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Drugs in R & D
hierarchy_parent_id	357171527
dewey-tens	610 - Medicine & health
hierarchy_top_title	Drugs in R & D
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)357171527 (DE-600)2094513-9
title	GP IIb/IIIa Antagonists
ctrlnum	(DE-627)SPR033286841 (SPR)00126839-199901050-00001-e
title_full	GP IIb/IIIa Antagonists
author_sort	Kleiman, Neal S.
journal	Drugs in R & D
journalStr	Drugs in R & D
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	1999
contenttype_str_mv	txt
container_start_page	361
author_browse	Kleiman, Neal S.
container_volume	1
class	610 ASE 44.40 bkl
format_se	Elektronische Aufsätze
author-letter	Kleiman, Neal S.
doi_str_mv	10.2165/00126839-199901050-00001
dewey-full	610
title_sort	gp iib/iiia antagonists
title_auth	GP IIb/IIIa Antagonists
abstract	Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.
abstractGer	Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.
abstract_unstemmed	Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190
container_issue	5
title_short	GP IIb/IIIa Antagonists
url	https://dx.doi.org/10.2165/00126839-199901050-00001
remote_bool	true
ppnlink	357171527
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00126839-199901050-00001
up_date	2024-07-03T17:44:28.297Z
_version_	1803580780891340800
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033286841</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519191741.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00126839-199901050-00001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033286841</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00126839-199901050-00001-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kleiman, Neal S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">GP IIb/IIIa Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Percutaneous Coronary Intervention</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Coronary Syndrome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Unstable Angina</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Abciximab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs in R & D</subfield><subfield code="d">[S.l.] : Springer International, 1999</subfield><subfield code="g">1(1999), 5 vom: Mai, Seite 361-370</subfield><subfield code="w">(DE-627)357171527</subfield><subfield code="w">(DE-600)2094513-9</subfield><subfield code="x">1179-6901</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:5</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:361-370</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00126839-199901050-00001</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1999</subfield><subfield code="e">5</subfield><subfield code="c">05</subfield><subfield code="h">361-370</subfield></datafield></record></collection>
score	7.400346

Nicht das Richtige dabei?

Schreiben Sie uns!

GP IIb/IIIa Antagonists

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?